Publicaciones en las que colabora con JUAN SANCHIS FORES (78)

2024

  1. Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: The modifying role of obesity

    Obesity Research and Clinical Practice, Vol. 18, Núm. 3, pp. 226-231

  2. CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction

    Clinical Kidney Journal, Vol. 17, Núm. 8

  3. Differential sex-related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study

    European Journal of Heart Failure, Vol. 26, Núm. 8, pp. 1687-1698

  4. Effect of exercise training in patients with chronotropic incompetence and heart failure with preserved ejection fraction: Training-HR study protocol

    Current Problems in Cardiology, Vol. 49, Núm. 12

  5. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 167-176

  6. Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trial

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 15, Núm. 2, pp. 681-689

  7. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure

    Scientific Reports, Vol. 14, Núm. 1

  8. Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters

    European Journal of Heart Failure

  9. Lower heart rate in patients with acute heart failure: the role of left ventricular ejection fraction

    Scandinavian Cardiovascular Journal, Vol. 58, Núm. 1

  10. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

  11. Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction—Impact on Tailored Lipid-Lowering Therapy at Discharge

    Journal of Clinical Medicine, Vol. 13, Núm. 1

  12. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  4. Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 264-273

  5. Role of plasma carbohydrate antigen 125 to identify nonfrail patients in HF

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 172-179

  6. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  7. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1